\n<\/p>\n
Global Live Biotherapeutic Product Market 2025-2034 full Research Repot latest version is now available.<\/p>\n
Get Free Access to Demo Report, Excel Pivot and ToC: https:\/\/www.insightaceanalytic.com\/request-sample\/1300<\/a><\/p>\n Latest Drivers Restraint and Opportunities Market Snapshot:<\/p>\n Key factors influencing the global live biotherapeutic product (LBP) market are: The following are the primary obstacles to the live biotherapeutic product (LBP) market’s expansion: Future expansion opportunities for the global live biotherapeutic product (LBP) market include: Key Industry Insights & Findings from the Report:<\/p>\n \u0095\tThe live biotherapeutic product (LBP) market is expanding rapidly due to improvements in the study of the microbiome and rising spending on customized treatment. Market Analysis: Furthermore, live biotherapeutic products (LBP) are a promising field in contemporary healthcare because of significant R&D investment, regulatory support for microbiome-based therapeutics, and the shift toward non-antibiotic treatments.<\/p>\n List of Prominent Players in the Live Biotherapeutic Product (LBP) Market:<\/p>\n \u0095\tSeres Therapeutics, Inc. Expert Knowledge, Just a Click Away: https:\/\/calendly.com\/insightaceanalytic\/30min?month=2025-03<\/a><\/p>\n Recent Developments: Live Biotherapeutic Product (LBP) Market Dynamics: The need for treatments based on the microbiota is growing as gastrointestinal disorders become more common. Moreover, LBPs provide tailored, non-antibiotic therapies that improve patient outcomes by restoring gut health. Market expansion is further accelerated by rising awareness and research on the gut microbiota, which further encourages adoption.<\/p>\n Challenges: High Manufacturing Cost Furthermore, LBPs are less available due to additional expenses associated with clinical studies, regulatory compliance, and storage restrictions. Moreover, despite the rising need for treatments that target the microbiome, these financial obstacles restrict development and uptake, which slows market growth.<\/p>\n North America Is Expected To Grow With The Highest CAGR During The Forecast Period The region\u0092s leadership in LBP development is also a result of expanded clinical trials, rising consumer awareness of gut health, and partnerships between biotech and pharmaceutical businesses, ensuring North America\u0092s place as an important marketplace.<\/p>\n Unlock Your GTM Strategy: https:\/\/www.insightaceanalytic.com\/customisation\/1300<\/a><\/p>\n Segmentation of Live Biotherapeutic Product (LBP) Market- About Us: Contact us:
\n\u0095\tIncreasing incidence of digestive disorders
\n\u0095\tIncreasing healthcare expenditure and growing awareness
\n\u0095\tInnovative technology <\/p>\n
\n\u0095\tHigh manufacturing cost
\n\u0095\tStrict regulatory compliance
\n\u0095\tLack of infrastructure<\/p>\n
\n\u0095\tIncreasing strategic partnerships with biotech companies
\n\u0095\tA growing interest in customized treatment
\n\u0095\tIncreased investment in research and development <\/p>\n
\n\u0095\tThe market for live biotherapeutic products (LBP) is driven by technological developments, heightened awareness of healthcare, and supportive government policies.
\n\u0095\tNorth America dominated the market and accounted for a revenue share of global revenue in 2023.
\n\u0095\tOne of the significant concerns restraining industry growth is the high manufacturing cost.<\/p>\n
\nThe live biotherapeutic product (LBP) market is driven by growing demand for tailored medication, increased awareness of gut health, and developments in microbiome research. The market is expanding due to the rising incidence of immune-related disorders, metabolic diseases, and gastrointestinal disorders. <\/p>\n
\n\u0095\tMicrobiotica
\n\u0095\tEnterome
\n\u0095\tDestiny Pharma plc
\n\u0095\tTaisho Pharmaceutical Holdings
\n\u0095\tAOBiome Therapeutics, Inc.
\n\u0095\tFinch Therapeutics Group, Inc
\n\u0095\tFerring Pharmaceuticals
\n\u0095\tRebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
\n\u0095\tMaaT Pharma
\n\u0095\tVedanta Biosciences Inc.
\n\u0095\tOxThera AB
\n\u0095\tPendulum Therapeutics
\n\u0095\tCaelus Health
\n\u0095\tQuorum Innovations
\n\u0095\tSanofi S.A
\n\u0095\tDermBiont, Inc.
\n\u0095\tEnteroBiotix Ltd
\n\u0095\tYSOPIA Bioscience
\n\u0095\tWinclove Probiotics
\n\u0095\tTargEDys
\n\u0095\tEvelo Biosciences, Inc.
\n\u0095\tBiomX
\n\u0095\tBiomica Ltd.
\n\u0095\tScioto Biosciences, Inc.
\n\u0095\tLactobio A\/S
\n\u0095\tTakeda Pharmaceutical Co. Ltd.
\n\u0095\tSecond Genome Therapeutics
\n\u0095\tJohnson and Johnson Inc.
\n\u0095\tKaleido Biosciences Inc.
\n\u0095\tOptiBiotix Health Plc
\n\u0095\tPureTech Health Plc
\n\u0095\tImmuron Limited
\n\u0095\tNaked Biome
\n\u0095\tSynthetic Biologics
\n\u0095\tExeGi Pharma
\n\u0095\tNexbiome
\n\u0095\tMybiotics Pharma LTD. <\/p>\n
\n\u0095\tIn January 2025, Microbiotica, a clinical-stage biopharma company that is creating a pipeline of oral precision microbiome medications known as live biotherapeutic products (LBPs), presented new information at the Keystone Symposia \u0093Human Microbiome.
\n\u0095\tIn December 2024, DermBiont, a clinical-stage biotechnology company, provided updates on its development pipeline. These included the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs and expected clinical milestones. Vermont is developing targeted topical therapeutics to address patient needs in three of the most commonly diagnosed dermatological indications.
\n\u0095\tIn September 2024, to treat patients with recurrent glioblastoma, Enterome, a clinical-stage company that is creating first-in-class immunomodulatory medications for solid and liquid cancers and inflammatory diseases using its proprietary Mimicry platform, announced the database lock of its Phase 2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +\/\u0097an anti-VEGF therapy (bevacizumab).<\/p>\n
\nMarket Drivers: Increasing Incidence of Digestive Disorders
\nOne of the main factors propelling the live biotherapeutic product (LBP) market is the rising prevalence of intestinal microbiota abnormalities and digestive illnesses. <\/p>\n
\nOne significant barrier to market expansion because of the high cost of manufacturing. The development of microbiome-based treatments raises production costs since it requires specialized facilities, sophisticated bioprocessing methods, and stringent quality control procedures.<\/p>\n
\nThe North American live biotherapeutic product (LBP) market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. This is because of the growing demand for personalized therapy, the incidence of digestive problems, and developments in microbiome research. Moreover, strong R&D expenditures and a thriving biotech sector all contribute to market growth.<\/p>\n
\nBy Product-
\n\u0095\tVOWST (SER-109)
\n\u0095\tREBYOTA
\n\u0095\tVisbiome
\n\u0095\tOther Pipeline Products
\nBy Target Disease Indication-
\n\u0095\tRecurrent C. Difficile Infection
\n\u0095\tIrritable Bowel Syndrome (IBS)
\n\u0095\tUlcerative Colitis (UC)
\n\u0095\tAntibiotic-associated diarrhea (AAD)
\n\u0095\tPouchitis
\n\u0095\tHepatic Encephalopathy (HE)
\n\u0095\tGraft Versus Host Disease
\n\u0095\tNecrotizing Enterocolitis
\n\u0095\tPrimary Hyperoxaluria
\n\u0095\tOthers
\nBy Route of Administration-
\n\u0095\tHospitals
\n\u0095\tDiagnostic Laboratories
\n\u0095\tOral Therapeutics
\n\u0095\tRectal Therapeutics
\nBy Region-
\nNorth America-
\n\u0095\tThe US
\n\u0095\tCanada
\n\u0095\tMexico
\nEurope-
\n\u0095\tGermany
\n\u0095\tThe UK
\n\u0095\tFrance
\n\u0095\tItaly
\n\u0095\tSpain
\n\u0095\tRest of Europe
\nAsia-Pacific-
\n\u0095\tChina
\n\u0095\tJapan
\n\u0095\tIndia
\n\u0095\tSouth Korea
\n\u0095\tSouth East Asia
\n\u0095\tRest of Asia Pacific
\nLatin America-
\n\u0095\tBrazil
\n\u0095\tArgentina
\n\u0095\tRest of Latin America
\n Middle East & Africa-
\n\u0095\tGCC Countries
\n\u0095\tSouth Africa
\n\u0095\tRest of Middle East and Africa<\/p>\n
\nInsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.<\/p>\n
\nInsightAce Analytic Pvt. Ltd.
\nVisit: www.insightaceanalytic.com<\/a>
\nTel : +1 551 226 6109
\nAsia: +91 79 72967118
\ninfo@insightaceanalytic.com
\n <\/p>\n<\/div>\n